Experimental combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT04098081
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have already tried at least two other therapies. Researchers will measure how many patients' tumors shrink and how long the disease is controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
galeterone and gemcitabine
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced pancreatic cancer who have run out of standard options.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply broadly. The drug combination may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States